agricultural leasing companies vancouver

Boosh Completes Studio Kitchen; Begins Filming Episodes

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) ("Boosh" or the "Company") is pleased to announce that it has completed its studio kitchen located at its greater Vancouver headquarters.

In January 2021, Boosh leased an 8,500 sq ft multi-purpose facility in greater Vancouver. The Company has been building out various aspects of the facility which include corporate offices, dry storage, freezer and refrigerated areas, and its studio which includes its filming kitchen and formal interview areas.

The studio will have interviews and guest appearances from local chefs, vegan athletes, and other trailblazers in the plant-based world. The completed videos and interviews will allow us to grow our online following and share our knowledge of adopting a plant-based lifestyle with individuals that may wish to learn more about alternative, plant-based eating styles.


Some of our regular programming will include:

Cooking with Boosh. This extended series will show how to use our products to create other healthy, nutritionally based meals. As an example, our new Boosh "Good Gravy" can easily be a cornerstone for a vegan holiday meal, and our own Boosh Chili for Chili Cheese Nachos for game day. All of our six frozen and three refrigerated entrées can be combined or adopted to create exceptionally healthy meals.

In addition, Boosh will be presenting "Veggie Hacks" which will be 15 to 30 second spots with unique, quality oriented, delicious plant-based recipes. Items in planning stages include fiery Szechwan green beans, ginger agave glazed carrots, garlic cashew cream alfredo and smokey stuffed portobellos.

In addition, our in-house nutritionist Haley Bellet will be presented, "Mind-Full of Health with Haley". Haley has a passion for food and promoting a healthy living lifestyle. She will be sharing her tips and advice for leading a productive, healthy, and balanced focused life.

"I studied to be a nutritionist and continued to grow my knowledge as the Wellness Manager at Nature's Fare market where I helped people take charge of their personal journey to heal and love, through healthy food choices, supplementation, and other modalities. Nature's Fare was one of the first places you could find delicious Boosh meals which is how I was introduced to Boosh and am absolutely delighted to be part of this amazing, forward thinking, plant loving team," exclaims Haley.

The company has purchased commercial grade equipment including cameras lighting, software, and hardware, as well as retain on a consulting basis a filming and post-edit professional to allow Boosh to produce high quality, visually appealing and education content.

On behalf of the Board of Directors

Jim Pakulis
Chief Executive Officer
Telephone: (833) 882-6674
www.Booshfood.com

Investor Relations
Contact - Edge Communications Group
Email: invest@booshfood.com
Telephone: (236) 237-1315

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), is the gateway to experiencing high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals which are sold throughout Canada, and now we're expanding our meals to include three refrigerated products. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94844

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's President and CEO, David Elsley, will present a company overview today which will be broadcast live at the Cantor Fitzgerald 2023 Global Healthcare Conference, at the InterContinental New York Barclay Hotel, on September 26, 2023, at 4:55 p.m. EDT.

Date: Tuesday, September 26, 2023
Time: 4:55 p.m. EDT
Live Video Webcast Link: www.wsw.com/webcast/cantor19/crdl/2077845

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS

Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients

Inaugural Scientific Summit Prioritized Advancing Translational Research, Pharmacodynamic Readouts and Innovative Biomarker-Driven Programs

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx for the Treatment of Acute Myocarditis

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx for the Treatment of Acute Myocarditis

Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule

Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 Patients

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday Sept. 14, 2023. Peter H. Griffith executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW LUMAKRAS® PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65%

Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS ® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). These results were featured in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) in Singapore on Sunday, September 10 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

  • Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)
  • 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen
  • No dose limiting toxicities to date

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

"The promising survival data of BriaCell's combination regimen suggests the potential for an industry-shaping leap in advanced metastatic breast cancer treatment," stated Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate Professor of Clinical Medicine, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ plus check point inhibitors study. "The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pre-treated patient population."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×